RecruitingPhase 2NCT05592015
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Studying T-cell large granular lymphocyte leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jonathan Brammer
- Principal Investigator
- Jonathan Brammer, MDOhio State University Comprehensive Cancer Center
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (3)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05592015 on ClinicalTrials.govOther trials for T-cell large granular lymphocyte leukemia
Additional recruiting or active studies for the same condition.
See all trials for T-cell large granular lymphocyte leukemia →